


CLAIMS

1. A compound of formula (I)



- 5 wherein R^2 is amino, a group OR^4 or a group $-Y-R^5$ where
 R^4 is hydrogen or C_{1-4} alkyl,
 Y is C_{1-4} alkylene,
 R^5 is hydrogen, halo, hydroxy, C_{1-2} alkoxy, C_{1-2} alkoxy C_{1-2} alkoxy C_{1-4} , or a group NR^7R^8
 10 where R^7 and R^8 are independently selected from hydrogen, C_{1-2} alkyl, hydroxy C_{1-2} alkyl
 or alkoxy C_{1-2} alkyl, or R^7 and R^8 together with the nitrogen atom to which they are
 attached form a saturated 5-6-membered heterocyclic ring which optionally contains an
 additional heteroatom;
 n is one or two and each R^1 is independently selected from halo, halo C_{1-2} alkyl, hydroxy,
 15 oxo, amino, C_{1-2} alkylamino or di- C_{1-2} dialkylamino;
 or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 wherein R^2 is a group- $Y-R^5$.
- 20 3. A compound according to claim 2 wherein Y is a C_{1-2} alkylene group.
4. A compound according to claim 2 or claim 3 wherein R^2 is methyl.
5. A compound according to claim 1 wherein R^2 is a group $-Y-R^5$ and R^5 is a
 25 group NR^7R^8 where R^7 and R^8 are independently selected from hydrogen, C_{1-2} alkyl,
 hydroxy C_{1-2} alkyl or alkoxy C_{1-2} alkyl, or R^7 and R^8 together with the nitrogen atom to


which they are attached form a saturated 5-6-membered heterocyclic ring which optionally contains an additional heteroatoms.

6. A compound according to any one of the preceding claims wherein n is 1.
- 5 7. A compound according to any one of the preceding claims wherein at least one R¹ group is a halo group.
8. A compound according to claim 7 wherein R¹ is bromo or chloro.
- 10 9. A compound according to any one of the preceding claims wherein an R¹ group is present at a position equivalent to the 5-position as numbered on the indole ring.
10. A compound according to claim 1 which is
- 15 6-{4-[4-(5-Chloro-1H-indole-2-sulphonyl)-piperazine-1-carbonyl]-phenyl}-2-methyl-2H-pyridazin-3-one,
1-(5-chloroindol-2-ylsulphonyl)-4-[4-(6-oxo-1-methyl-pyridazin-3-yl)benzoyl]piperazine,
6-[4-({4-[(5-chloro-1H-indol-2-yl)sulphonyl]piperazin-1-yl}carbonyl)phenyl]-2-[2-(dimethylamino)ethyl]pyridazin-3(2H)-one,
- 20 6-{4-[4-(5-chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2-(2-methylamino-ethyl)-2H-pyridazin-3-one,
6-{4-[4-(5-chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2-ethyl-2H-pyridazin-3-one,
- 25 2-butyl-6-{4-[4-(5-chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2H-pyridazin-3-one,
6-{4-[4-(5-chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2-(2-hydroxy-ethyl)-2H-pyridazin-3-one,
6-{4-[4-(5-chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2-(2,2,2-
- 30 trifluoro-ethyl)-2H-pyridazin-3-one,
6-{4-[4-(5-chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2-(2-methoxy-ethyl)-2H-pyridazin-3-one,

- 6-[4-({4-[(5-chloro-1H-indol-2-yl)sulphonyl]piperazin-1-yl}carbonyl)phenyl]-2-[2-(2-methoxyethoxy)ethyl]pyridazin-3(2H)-one,
 6-{4-[4-(5-Chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2-fluoromethyl-2H-pyridazin-3-one,
 5 6-{4-[4-(5-Chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2-difluoromethyl-2H-pyridazin-3-one or
 6-{4-[4-(5-Chloro-1H-indole-2-sulfonyl)-2-oxo-piperazin-1-ylmethyl]-phenyl}-2-(2-morpholin-4-yl-ethyl)-2H-pyridazin-3-one.


- 10 11. A process for preparing a compound of formula (I) as defined in claim 1 which process comprises either

(a) reacting an amine of formula (II)



(II)

with an acid of the formula (III)




(III)

15

or a reactive derivative thereof; or

(b) reacting a compound of the formula (VIII):




(VIII)

20

wherein Z' is a displaceable group, with a compound of formula (IX)

32




(IX)

wherein R^2 is as defined claim 1 and A is an activating group, or


(c) forming a substituted pyridazinone ring on compounds of formula (VIII), wherein Z' is a functional group capable of cyclisation;

5 (d) by reacting a compound of the formula (X):



(X)


where R^2 is as defined in claim 1, with a compound of the formula (XI):



(XI)

wherein R^1 and n are as defined in claim 1 and Z'' is a displaceable group, under conditions similar to those described above in process (a); or

(e) reacting a compound of formula (XIII)



(XIII)

wherein R^1 and n are as defined claim 1, and the indole ring is optionally protected, with a compound of formula (A)



where R^2 is as defined in claim 1 and Z''' is a displaceable group, and thereafter if
5 necessary, removing any indole protecting groups.

12. A compound of formula (I), as defined in any claim from 1 to 8, or a pharmaceutically-acceptable salt thereof for use in medical therapy.
- 10 13. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically-acceptable salt thereof, as defined in any claim from 1 to 8, with a pharmaceutically-acceptable diluent or carrier.
14. Use of a compound of formula (I), as defined in any claim from 1 to 10, or a
15 pharmaceutically-acceptable salt thereof, in the preparation of a medicament for use in a method of treating a Factor Xa mediated disease or condition.
15. A method of treating a Factor Xa mediated disease or condition in a warm-blooded animal comprising administering an effective amount of a compound of
20 formula (I), as defined in any claim from 1 to 10, or a pharmaceutically-acceptable salt thereof.